Daiichi Signs Tesetaxel Development Rights to Genta
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo has signed a deal with Genta that grants the Berkeley Heights, N.J.-based firm development and commercialization rights to Daiichi's oral taxane tesetaxel, the firms said March 7